Videx Articles
US FDA warns on liver disorder associated with the use of Bristol-Myers Squibb’s Videx
1 February 2010
GSK warns of potential heart risk for HIV drug
30 June 2008
FDA starts safety review of GSK and B-MS HIV drugs
7 April 2008
CHMP requests Ziagen data to assess heart risk
7 April 2008
UPDATE: Indonesia considers three more CLs
10 December 2007
Indonesia considers three more CLs
10 December 2007
B-MS 1st-qtr 2005 income down 36%
9 May 2005
South Africa awards ARV drug tenders
14 March 2005
MSF calls for generic 2nd-line ARV combos
19 July 2004
Positive Ph III data with Triangle's emtricitabine
17 February 2003
Triangle's Coviracil trial "un-blinded"
5 August 2002
Thailand urged over essential drug patents
17 June 2002
Kenyan HIV/AIDS drug shortages hit patients
29 April 2002
B-MS launches HIV treatment Videx EC in Canada
14 January 2002
Initial therapy with Viracept may avoid emergence of HIV "superbugs"
24 December 2001
Glead's Viread for HIV set for launch in USA "within days"
29 October 2001
Merck & Co, B-MS cut drug prices further
20 March 2001
Warnings issued on use of B-MS' antiretrovirals in pregnancy
8 January 2001
B-MS wins FDA OK for new Videx drug
3 November 2000
First cheap HIV drugs for Senegal
26 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
Indian firms to launch new drugs this fiscal year
29 August 2000
HIV/AIDS therapy sales forecasts to 2009
3 August 2000
Thailand boosts locally- made HIV generics
30 June 2000
B-MS' Vanlev "more effective" than lisinopril
23 March 2000
B-MS gets first approval for new Videx
24 February 2000
New data with Triangle's emtricitabine
3 February 2000
B-MS files for new Videx formulation
2 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Thailand "plans B-MS' Videx compromise"
19 January 2000
Thailand tests USA's new trade line on drugs
21 December 1999
Videx goes once-daily in USA
4 November 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
FDA OKs expanded indications for B-MS' Zerit and Videx
10 September 1999
B-MS South Africa deal for AIDS program
7 September 1999
BioChem Pharma starts Phase II troxacitabine
8 April 1999
New trials support role of nevirapine in HIV
29 March 1999
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
A Real Challenge To HIV With New Therapies?
12 February 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
HIV News In Brief: Research And Trials
20 October 1997
NDA Filed For New Soft-Gel Saquinavir
9 October 1997
Role For Didanosine In Toxoplasmosis?
17 July 1997
AIDS Study Terminated In Children
3 July 1997
B-MS Licenses Novartis HIV Protease Inhibitors
9 June 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
Spanish Health Care Spending On AIDS
13 January 1997
B-MS Gains Rights For Eisai Antifungal
23 December 1996
Split Verdict From Panel On P&U's Delavirdine
2 December 1996
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Delavirdine Filed In USA; NNRTI Role Reviewed
29 July 1996
Hydroxyurea Enhances Didanosine Effects
29 July 1996
Can HIV be Eradicated From An Infected Person?
1 July 1996
Volume Growth Boosts B-MS' First Quarter
6 May 1996
Antivirals "Now 9% Of Anti-Infectives Market"
11 March 1996
Moves In HIV Therapy As FDA Panel Delivers Verdicts
4 March 1996
Triple Therapies For HIV Provide Encouraging Data
5 February 1996
Delta Trial Gives Boost To AIDS Community
2 October 1995
B-MS Shows Benefits Of Antiretroviral Therapy
25 September 1995
Bristol-Myers research operations
31 July 1995
Bristol-Myers Squibb Has "Best Combo Of Businesses"
20 February 1995
Robb Claims Wellcome Is Undervalued By Glaxo
20 February 1995
Zidovudine Arm Of ACTG 152 Halted
20 February 1995
HIV Therapy Options Examined
31 October 1994
Wellcome Details HIV Research Plans
15 August 1994
Panel Backs Indication Extension For Retrovir
8 August 1994
PROMPT APPROVAL OF B-MS' STAVUDINE
4 July 1994
UK LAUNCH OF DIDANOSINE
27 June 1994
FIRMS TO SHARE AIDS DRUG TRIAL DATA
25 April 1994
HIVID AS EFFECTIVE AS VIDEX
21 March 1994
ZALCITABINE AS EFFECTIVE AS DIDANOSINE
14 March 1994
CALL FOR US FDA AIDS DRUG COMMITTEE
7 February 1994
STRONG DOLLAR WEAKENS US 1993 RESULTS
31 January 1994
B-MS SEEKS APPROVAL TO SELL STAVUDINE
17 January 1994
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
US 3rd QTR AFFECTED BY STRONG DOLLAR
1 November 1993
US PANEL BACKS HIVID AS MONOTHERAPY...
4 October 1993
SINGAPORE CHARITY BUYS AIDS DRUGS
20 September 1993
MERCK DISCONTINUES L661 DEVELOPMENT
20 September 1993
SPAIN LICENSES DIDANOSINE
12 July 1993
US NIH ON FENCE OVER EARLY-STAGE RETROVIR
5 July 1993
COMBINATION THERAPIES IN AIDS: LITTLE PROGRESS
21 June 1993
DIDANOSINE REGISTRATION IN EC
24 May 1993
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
